Vantage Consulting Group Inc Supernus Pharmaceuticals, Inc. Transaction History
Vantage Consulting Group Inc
- $7.71 Million
- Q3 2024
Shares
2 transactions
Others Institutions Holding SUPN
# of Institutions
282Shares Held
60.9MCall Options Held
27.7KPut Options Held
11.3K-
Black Rock Inc. New York, NY10.4MShares$376 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.13MShares$221 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.1MShares$184 Million2.64% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$104 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$95.1 Million0.09% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.93B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...